Broadwood Partners, L.P. Acquires 2,000,000 Shares of OncoCyte Corp (NYSEAMERICAN:OCX) Stock

OncoCyte Corp (NYSEAMERICAN:OCX) major shareholder Broadwood Partners, L.P. acquired 2,000,000 shares of OncoCyte stock in a transaction dated Wednesday, September 11th. The stock was bought at an average price of $1.66 per share, for a total transaction of $3,320,000.00. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

  • On Tuesday, July 2nd, Broadwood Partners, L.P. acquired 1,000,000 shares of OncoCyte stock. The stock was bought at an average price of $2.00 per share, for a total transaction of $2,000,000.00.

OncoCyte stock opened at $2.22 on Thursday. OncoCyte Corp has a 52 week low of $1.16 and a 52 week high of $6.92.

OncoCyte (NYSEAMERICAN:OCX) last released its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.10) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.10).

OCX has been the subject of several analyst reports. Benchmark reiterated a “buy” rating on shares of OncoCyte in a research note on Wednesday, July 3rd. Zacks Investment Research lowered OncoCyte from a “buy” rating to a “hold” rating in a research note on Wednesday, July 24th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. OncoCyte has a consensus rating of “Buy” and an average price target of $6.10.

Institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its stake in OncoCyte by 1,136.2% during the second quarter. BlackRock Inc. now owns 1,553,990 shares of the biotechnology company’s stock worth $3,869,000 after acquiring an additional 1,428,288 shares during the last quarter. Maven Securities LTD acquired a new stake in OncoCyte during the second quarter worth about $550,000. Vanguard Group Inc. increased its stake in OncoCyte by 12.4% during the second quarter. Vanguard Group Inc. now owns 1,413,924 shares of the biotechnology company’s stock worth $3,521,000 after acquiring an additional 156,505 shares during the last quarter. Jane Street Group LLC increased its stake in OncoCyte by 496.4% during the second quarter. Jane Street Group LLC now owns 71,342 shares of the biotechnology company’s stock worth $178,000 after acquiring an additional 59,379 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in OncoCyte by 299.1% during the second quarter. Bank of New York Mellon Corp now owns 77,719 shares of the biotechnology company’s stock worth $194,000 after acquiring an additional 58,246 shares during the last quarter.

OncoCyte Company Profile

OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.

See Also: What is the price-sales ratio?

Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.